Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | LTC4S | Q16873 | 5/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4823642 | 0.85 | IDO1 (0.34) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4823417 | 0.85 | MEN1 (0.39) | MEN1KMT2AALDH1A1LMNANAPRT | |
| SCHEMBL4669089 | 0.84 | POLB (0.35) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL4820601 | 0.84 | OXTR (0.31) | — | |
| SCHEMBL4824601 | 0.84 | MEN1 (0.44) | MEN1KMT2AALDH1A1LMNALTC4S | |
| Hydrochloric Acid SCHEMBL4670894 | 0.83 | POLB (0.34) | MEN1KMT2AALDH1A1LMNAPOLB | |
| SCHEMBL4818544 | 0.82 | KMT2A (0.41) | MEN1KMT2AALDH1A1LMNANAPRT | |
| SCHEMBL3141927 | 0.79 | CYP11B1 (0.32) | ALDH1A1LMNA | |
| SCHEMBL4824084 | 0.77 | KMT2A (0.38) | MEN1KMT2AALDH1A1LMNANAPRT | |
| SCHEMBL6290174 | 0.76 | CHRNB2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146621-A1 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | LES LABORATORIES SERVIER (FR) | 2008-06-19 | — | — | US | disclosed |
| US-7388022-B2 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2008-06-17 | — | — | US | disclosed |
| US-20070027192-A1 | Polysubstituted 1,1-pyridylamioncyclopropanamine compounds | LES LABORATOIRES SERVIER (FR) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146621-A1 | Polysubstituted 1,1-pyridylaminocyclopropanamine compounds | CHRNA1, CHRM1, CHRNA9 | MEN1 3199/4885KMT2A 2105/4885ALDH1A1 531/4885 |
| US-20070027192-A1 | Polysubstituted 1,1-pyridylamioncyclopropanamine compounds | CHRM1, CHRM2, CHRM3 | MEN1 2023/4885KMT2A 2287/4885ALDH1A1 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.